{
    "data": [
        {
            "title": "Assessing Silverco Mining (TSXV:SICO) After Final 2025 Cusi Drill Results And Strong Recent Share Price Gains",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Silverco Mining (TSXV:SICO) has drawn fresh attention after reporting the final assay results from its 15,000 metre 2025 diamond drill program at the 100% owned Cusi Property in Chihuahua, Mexico.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Silverco Mining.</a></p> <p>The recent drilling update and February equity raise appear to be part of the backdrop to Silverco Mining‚Äôs strong momentum, with a 7 day share price return of 17.7%, a 30 day return of 25.6%, and a 90 day return of 140.4% from a latest share price of CA$13.82. Together, these figures suggest building optimism around the exploration story rather than short term trading alone.</p> <p>If this kind of move in a silver focused explorer has your attention, it could be worth widening your search with our screen of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_silver\" href=\"https://simplywall.st/discover/investing-ideas/473743/top-silver-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">7 top silver producer stocks</a> to see what else is on the radar.</p> <p>With zero revenue, a recent equity raise at CA$12.50 and a share price at CA$13.82 after very strong recent returns, you have to ask: is Silverco still mispriced, or is the market already banking on future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 93.1% Undervalued</h2> <p>According to the most followed narrative, Silverco Mining‚Äôs fair value of CA$199 sits far above the last close at CA$13.82, which frames the recent rally in a very different light.</p> <blockquote> <p><em>Silverco is a restart-stage, high-grade-ish silver district consolidator advancing the Cusi Mine Complex (underground mine + permitted 1,200 tpd mill) toward a restart decision, but the company explicitly says no production decision has been made yet, pending technical, financial, and permitting milestones.</em></p> </blockquote> <p><em>üó∫Ô∏è Expected Timeline to Full Production 2026 (company framing): ‚Äúresource update / restart plan / restart operations‚Äù (high-level). However, the official stance is that no production decision has been made yet until milestones are completed. Practical interpretation: until Silverco releases a restart study, financing, and a detailed schedule, any exact ‚Äúfull production‚Äù date would be guesswork.</em></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/0ox1qy9t-update-for-silverco-mining\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious how a zero revenue explorer gets to that CA$199 figure? The narrative leans on projected ounces, margins and a rich implied multiple that is far from conservative.</p> <p><strong>Result: Fair Value of CA$199 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/0ox1qy9t-update-for-silverco-mining\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this narrative could quickly be tested if the restart decision is delayed further or if new technical work points to persistently high AISC.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Silverco Mining narrative.</a></p> <h2>Next Steps</h2> <p>If this all sounds optimistic or cautious to you, it is worth checking the facts yourself and forming your own take, especially given our findings of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Silverco has sparked your curiosity, do not stop here. Broaden your watchlist now with focused screens that surface opportunities you might otherwise miss.</p> <ul> <li>Scan for potential bargains by checking companies highlighted in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a>, where pricing and fundamentals can tell a very different story to the headline narrative.</li> <li>Strengthen the quality of your watchlist by focusing on companies from the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/ca\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (10 results)</a>, so you are not ignoring balance sheet resilience.</li> <li>Spot under followed opportunities early by reviewing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/ca\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 6 high quality undiscovered gems</a>, before they sit firmly on everyone else‚Äôs radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:56:03",
            "link": "https://simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares/news/assessing-silverco-mining-tsxvsico-after-final-2025-cusi-dri",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Vulcan Materials (VMC) Fully Priced After Strong Multi Year Share Price Gains",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Vulcan Materials is a fair deal at around US$310 per share, it helps to step back and look at what the current price actually reflects.</li> <li>The stock last closed at US$310.00, with returns of 1.5% over 7 days, 3.1% over 30 days, 5.9% year to date, 26.3% over 1 year, 73.4% over 3 years and 92.3% over 5 years, which may shape how investors are thinking about its potential and its risks today.</li> <li>Recent coverage has focused on Vulcan Materials as a key supplier of construction aggregates in the US, with investors watching how its position in infrastructure and construction projects could influence sentiment. At the same time, broader market discussions around materials and construction stocks have given context to Vulcan's share price moves, as investors compare it to peers and sector trends.</li> <li>Despite that backdrop, Vulcan Materials currently has a valuation score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">0 out of 6</a>. Next, we will look at how different valuation approaches, and a more holistic view at the end of the article, might help you judge whether the current price lines up with your own expectations.</li> </ul> <p>Vulcan Materials scores just 0/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Vulcan Materials Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today to get a single present value per share.</p> <p>For Vulcan Materials, the model used is a 2 Stage Free Cash Flow to Equity approach that starts from last twelve months free cash flow of about $1.07b. Analysts provide explicit projections through 2028, with free cash flow for that year modeled at $1.60b. Beyond that, Simply Wall St extrapolates out to 2035, generating a full 10 year cash flow path in dollar terms.</p> <p>When all those projected cash flows are discounted back, the DCF output points to an estimated intrinsic value of about $269.82 per share. Compared with the recent share price of US$310.00, this output indicates that Vulcan Materials is around 14.9% overvalued on this model.</p> <p>On this DCF view, the current market price is above the modelled cash flow value.</p> <p><strong>Result: OVERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Vulcan Materials may be overvalued by 14.9%. <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">Discover 46 high quality undervalued stocks</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">create your own screener</a> to find better value opportunities.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"VMC Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b5c73fc4-1c78-42f4-b741-436f7057bd54/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>VMC Discounted Cash Flow as at Mar 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Vulcan Materials.</a></p> <h3>Approach 2: Vulcan Materials Price vs Earnings</h3> <p>For a profitable company like Vulcan Materials, the P/E ratio is a useful way to see how much investors are currently paying for each dollar of earnings. In general, higher expected earnings growth or lower perceived risk can support a higher P/E, while lower growth or higher risk tends to align with a lower, more cautious multiple.</p> <p>Vulcan Materials is trading on a P/E of 37.44x. That compares with an average P/E of 15.56x for the wider Basic Materials industry and a peer group average of 27.79x, so the stock is priced above both of those reference points. Simply Wall St also calculates a proprietary ‚ÄúFair Ratio‚Äù for Vulcan Materials of 24.44x. This is the P/E it might trade on given factors such as its earnings growth profile, profit margins, industry, market capitalization and risk characteristics.</p> <p>This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific drivers rather than assuming one size fits all. Lining up the current P/E of 37.44x against the Fair Ratio of 24.44x suggests Vulcan Materials is trading at a richer multiple than this model would indicate.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:VMC P/E Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b5c73fc4-1c78-42f4-b741-436f7057bd54/chart/pe-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NYSE:VMC P/E Ratio as at Mar 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Vulcan Materials Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your own story about a company that you connect to a forecast for revenue, earnings and margins, then to a Fair Value that you can compare with the current price.</p> <p>On Simply Wall St, Narratives live in the Community page and are designed to be easy to use. You can plug in the assumptions you believe in, see the Fair Value that falls out of those numbers, and quickly judge whether that is above or below Vulcan Materials' current share price.</p> <p>Because Narratives update as new information comes in, such as earnings, guidance or news about highway spending and buybacks, your story and its Fair Value do not stay frozen. They move with the data so you can keep checking whether the gap between price and value still supports holding, trimming or adding.</p> <p>For Vulcan Materials, one investor might build a more optimistic Narrative closer to US$340 per share that leans on stronger infrastructure demand and margin expansion. Another might prefer a more cautious Narrative nearer US$190 to US$239.78 per share that leans on sustainability pressures, regulation and slower construction. Both can see in one place how their different stories link to different Fair Values and decisions.</p> <p>For Vulcan Materials, however, we will make it really easy for you with previews of two leading Vulcan Materials Narratives:</p> <p><a href=\"/us/materials/nyse-vmc/vulcan-materials/0leo7c01-highway-project-spending-and-pricing-trends-will-sustain-balanced-opportunity-ahead?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Vulcan Materials Bull Case</strong></a></p> <p>Fair value in this bullish Narrative: US$327.57 per share</p> <p>Gap to that fair value at the recent US$310.00 price: about 5.4% below the Narrative fair value</p> <p>Revenue growth assumption used: 5.34% a year</p> <ul> <li>Analysts in this camp expect infrastructure spending, Sunbelt demand and disciplined pricing to support revenue and earnings over several years.</li> <li>They factor in higher profit margins over time, supported by cost control, automation, acquisitions and a steady project pipeline.</li> <li>Their numbers line up with an analyst consensus price target around US$304.05 and a fair value estimate near US$327.57, with the view that the current price is broadly in line with those assumptions.</li> </ul> <p><a href=\"/us/materials/nyse-vmc/vulcan-materials/3wytubgl-shifting-urbanization-and-sustainability-will-erode-traditional-aggregates?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Vulcan Materials Bear Case</strong></a></p> <p>Fair value in this bearish Narrative: US$264.31 per share</p> <p>Gap to that fair value at the recent US$310.00 price: about 14.8% above the Narrative fair value</p> <p>Revenue growth assumption used: 8.75% a year</p> <ul> <li>This group flags long term headwinds from sustainability trends, regulation, reserve quality and alternative building methods that could pressure traditional aggregate demand.</li> <li>They still model revenue and earnings growth, but think the P/E multiple implied by the current price asks too much of future execution and market conditions.</li> <li>Their updated fair value of about US$264.31 reflects those concerns, with the view that recent gains leave less room for error.</li> </ul> <p>Taken together, these Narratives frame a clear range for Vulcan Materials, from a more optimistic fair value near US$327.57 to a more cautious one around US$264.31. Your own view on volumes, margins and the P/E you are comfortable with will decide which story feels closer to reality.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Vulcan Materials? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/VMC\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-vmc/vulcan-materials\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:VMC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b5c73fc4-1c78-42f4-b741-436f7057bd54/chart/quote-price?date=2026-03-01\" width=\"746\"/></a><figcaption>NYSE:VMC 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:56:03",
            "link": "https://simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/news/is-vulcan-materials-vmc-fully-priced-after-strong-multi-year",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Xponential Fitness (XPOF) Valuation After Weak Earnings And Lower 2026 Revenue Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Xponential Fitness.</a></p> <p>The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of risk.</p> <p>If you are reassessing your exposure to consumer names after this update, it could be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With revenue at US$314.9 million in 2025, a net loss of US$38.7 million and 2026 guidance pointing lower, the steep share price pullback raises the key question: is XPOF now undervalued, or is the market correctly pricing in weaker growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 60.9% Undervalued</h2> <p>With Xponential Fitness closing at $4.26 against a widely followed fair value estimate of $10.90, the current setup reflects a wide valuation gap that hinges on long term assumptions about profitability and growth durability.</p> <blockquote> <p><em>The analysts have a consensus price target of $12.333 for Xponential Fitness based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $9.0.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/k97fvnpr-international-expansion-will-capture-rising-wellness-demand-wotn\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what sits behind that fair value gap and wide analyst range? The narrative leans heavily on a sharp swing to profitability, higher margins and a future earnings multiple that assumes the franchise model keeps scaling efficiently. The exact mix of revenue growth, margin lift and discount rate doing the heavy lifting is all laid out in the full narrative.</p> <p><strong>Result: Fair Value of $10.90 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/k97fvnpr-international-expansion-will-capture-rising-wellness-demand-wotn\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, softer same-store sales and slower studio openings, combined with higher closures and leverage, could pressure royalties and challenge the bullish profitability path that analysts are using.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Xponential Fitness narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of concern and optimism feels familiar, do not wait on the sidelines. Check the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> to weigh the full picture for yourself.</p> <h2>Looking for more investment ideas?</h2> <p>If Xponential Fitness has you rethinking your watchlist, do not stop here. Use this moment to widen your opportunity set with a few focused stock ideas.</p> <ul> <li>Spot potential bargains first by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that pair quality with prices that may not fully reflect their fundamentals.</li> <li>Prioritise resilience with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> so you can focus on companies that score well on stability instead of constantly worrying about shocks.</li> <li>Get ahead of the crowd by checking our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before these names move onto everyone else's radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 19:56:03",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness/news/assessing-xponential-fitness-xpof-valuation-after-weak-earni",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Collegium Pharmaceutical (COLL) shares came under pressure after its Q4 and full year 2025 report, where earnings and revenue missed some analyst estimates, while management reaffirmed and slightly lifted 2026 guidance.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Collegium Pharmaceutical.</a></p> <p>The Q4 miss has come with a reset in expectations, with the 1 day share price return of a 5.77% decline at US$41.67 extending a 30 day share price return of a 9.26% decline, even though the 1 year total shareholder return of 43.44% and 5 year total shareholder return of 85.28% still point to investors who have stayed invested being rewarded over time.</p> <p>If this mix of short term volatility and longer term gains has you thinking about other opportunities in healthcare, it could be worth scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> as a starting list of ideas.</p> <p>With Collegium still trading below the average analyst price target and recent results combining record revenues with an earnings miss, you have to ask: Is this pullback a reset that leaves upside on the table, or is the market already baking in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 22.4% Undervalued</h2> <p>Collegium Pharmaceutical's widely followed narrative pegs fair value at about $53.67 per share versus the last close of $41.67, framing the current pullback as potentially too harsh in the context of long term earnings power.</p> <blockquote> <p><em>The company's differentiated pain portfolio, notably with products featuring proprietary abuse deterrent and extended release technologies (e.g., Xtampza ER's DETERx platform), is supported by industry and regulatory trends that increasingly favor safer opioid options. This likely enhances market share, pricing power, and sustains net margins as regulatory emphasis on abuse deterrence grows.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what kind of profit margins and earnings path have to line up with that view? The most followed narrative leans on a very specific mix of modest revenue shifts, rising profitability and a future earnings multiple that is lower than many peers expect. The numbers behind that story are where the real tension sits.</p> <p><strong>Result: Fair Value of $53.67 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also need to weigh risks, such as potential generic pressure on key pain brands and higher operating costs if expected Jornay PM traction does not fully show up.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Collegium Pharmaceutical narrative.</a></p> <h2>Another View: Multiples Paint A Pricier Picture</h2> <p>So far, the story leans on cash flows and long term earnings power suggesting Collegium looks undervalued. Yet on a simpler yardstick like P/E, the stock trades around 21x, above both peers at 18.1x and a fair ratio estimate of 18.2x. This suggests there may be less room for error if growth or margins disappoint.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:COLL P/E Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9a27ea2f-6e12-4a81-a52d-45f720512ada/chart/pe-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NasdaqGS:COLL P/E Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>Given the mixed signals in the story so far, it makes sense to move quickly and look through the numbers yourself, weighing up both sides of the argument. To see how the current share price lines up with the balance of risks and potential rewards, take a closer look at the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this earnings update has sharpened your focus, do not stop here; broaden your watchlist with a few targeted screens that surface different kinds of opportunities.</p> <ul> <li>Spot potential bargains early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that pair solid fundamentals with limited market attention.</li> <li>Build a foundation of strength by checking companies in the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a> that prioritise robust financial footing.</li> <li>Aim for a smoother ride by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> that score well on our risk metrics while still offering upside potential.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 19:56:03",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/a-look-at-collegium-pharmaceutical-coll-valuation-after-mixe",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity offering and filing additional shelf capacity linked to employee stock plans.</li> <li>Alongside these financing moves, the company highlighted unprecedented Phase 2 results for its VAX-31 pneumococcal vaccine, rapid progression into multiple Phase 3 trials, and completion of a large-scale manufacturing facility that together signal a major push toward potential commercialization of its vaccine portfolio.</li> <li>Next, we‚Äôll examine how Vaxcyte‚Äôs unprecedented VAX-31 Phase 2 data and advancing Phase 3 program shape the company‚Äôs investment narrative.</li> </ul><p>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is Vaxcyte's Investment Narrative?</h2><p>For Vaxcyte, the core belief you need to have as a shareholder is that its pneumococcal and broader vaccine pipeline can translate extensive cash burn today into meaningful, defensible products tomorrow. The latest update sharpens that tradeoff. On one hand, the 2025 net loss widening to US$766.63 million reinforces that this is a pure clinical-stage story with no revenue and rising operating costs. On the other, raising about US$408.10 million via an at-the-market equity program, layering on new shelf capacity tied to employee stock plans, reporting unprecedented VAX-31 Phase 2 data, moving quickly into several Phase 3 trials and finishing a large-scale manufacturing facility all feed directly into the near-term catalysts: clinical readouts, regulatory milestones and potential partnering discussions. The key risk profile also shifts slightly, with financing risk reduced for now but dilution, trial execution and commercial build-out risks front and center. Overall, the February 2026 news is material because it both extends the funding runway and accelerates the company toward its most binary events.</p> However, investors should not overlook how rising losses and ongoing dilution could affect future outcomes.\n\nVaxcyte's shares have been on the rise but are still potentially undervalued by 33%. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Find out what it's worth</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PCVX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a5c22673-aeb2-4b4c-9e84-eb62a6baad5a/chart/quote-price\" width=\"746\"/></a><figcaption>PCVX 1-Year Stock Price Chart</figcaption></figure> Three Simply Wall St Community fair values, from US$10.90 to US$109.00, show just how far apart expectations sit. Set against escalating losses and heavier reliance on trial success, it underlines why you should weigh multiple viewpoints before deciding how Vaxcyte fits in your portfolio.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Vaxcyte</a> - why the stock might be worth as much as 77% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Vaxcyte research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Vaxcyte research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:56:03",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-55-after-unveiling-vax-31-data-phase-3-pl",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. </li> <li>The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU‚Äôs target markets. </li> <li>We‚Äôll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU‚Äôs commercialization may influence EyePoint‚Äôs broader investment narrative. </li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">31 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>EyePoint Investment Narrative Recap</h2><p>To own EyePoint today, you really have to believe DURAVYU can graduate from a Phase 3 program into a meaningful commercial franchise before cash burn becomes overwhelming. The Michael Campbell hire directly targets the key short term catalyst, a potential DURAVYU launch, but it does not change the fact that any delay or disappointment in the pivotal trials remains the central risk for a company with minimal current revenue.</p> <p>Among recent announcements, the Phase 3 DURAVYU update following the second DSMC review in November 2025 is most relevant here, because it kept the pivotal program on track toward potential commercialization. Campbell‚Äôs arrival now sits on top of that clinical backdrop, linking trial progress with an increasingly built out launch and manufacturing footprint, which together frame both the upside catalyst of a successful entry into wet AMD and DME and the execution risk if uptake proves slower than expected.</p> <p>Yet against that excitement, investors should be aware that...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/nwrya9z6-phase-iii-trials-in-wet-amd-will-expand-market-reach-ncqs\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on EyePoint (it's free!)</a></p><p>EyePoint's narrative projects $146.7 million revenue and $34.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/nwrya9z6-phase-iii-trials-in-wet-amd-will-expand-market-reach-ncqs\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how EyePoint's forecasts yield a $36.08 fair value</a>, a 105% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"EYPT 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3922204e-9934-411a-90c5-e170feacb161/chart/quote-price\" width=\"746\"/></a><figcaption>EYPT 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest estimate analysts were assuming only about 7.9% annual revenue growth and ongoing losses, so compared with those views, you should see Campbell‚Äôs appointment and the Phase III dependence as parts of a much more cautious story that might look different once updated forecasts reflect this new hire.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on EyePoint</a> - why the stock might be worth just $36.08!</p><h2>Reach Your Own Conclusion</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your EyePoint research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\">Our free EyePoint research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>The latest GPUs need a type of rare earth metal called Neodymium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if EyePoint might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 19:46:58",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/is-eyepoint-eypt-recasting-its-ophthalmology-playbook-with-a",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Aisin (TSE:7259) Valuation After Leadership Transition At The Top",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Leadership change as a fresh lens on Aisin stock</h2> <p>Aisin (TSE:7259) is back in focus after its Board of Directors decided to change the company‚Äôs representative directors, putting a leadership transition at the center of the investment story.</p> <p>From April 1, 2026, Yoshihisa Yamamoto is set to become Executive Vice President and Representative Director, while Shintaro Ito plans to retire from senior executive roles and be proposed as an Audit &amp; Supervisory Board Member at the June 2026 shareholders‚Äô meeting.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Aisin.</a></p> <p>The leadership reshuffle comes after a mixed price backdrop, with the 1 day share price return of 2.39% and 7 day return of 3.64% sitting against a year to date share price decline of 7.47%. At the same time, longer term total shareholder returns of 61.69% over one year and 168.29% over five years point to gains that investors will compare with current expectations.</p> <p>If this leadership news has you thinking more broadly about where growth could come from in mobility and manufacturing, it might be worth scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_robotics\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 robotics and automation stocks</a> as a fresh set of ideas to review next.</p> <p>With Aisin trading at ¬•2,779.5 and sitting at an estimated 45% discount to one intrinsic value measure and around 9% below the average analyst price target, is there still a buying opportunity here, or is the market already pricing in future growth?</p> <h2>Preferred P/E of 12.2x: Is it justified?</h2> <p>Aisin's current P/E of 12.2x sits at an interesting crossroads, with the shares at ¬•2,779.5 and various signals pointing in different directions compared with both peers and an internally estimated fair ratio.</p> <p>The P/E multiple compares the company‚Äôs share price with its earnings per share, so it essentially reflects what investors are currently willing to pay for each unit of profit. For an auto components group like Aisin, this is a common yardstick because earnings are a direct link to its large base of recurring supply contracts and exposure to vehicle production volumes.</p> <p>Here, the picture is mixed. On one hand, Aisin is described as expensive versus the broader JP Auto Components industry average P/E of 11.4x, which suggests the market is paying a premium relative to many sector peers. On the other hand, the same 12.2x P/E is assessed as good value compared with an estimated fair P/E of 15.5x, as well as against a peer average of 19.3x in a separate comparison. Those reference points imply that if valuations shifted closer to the higher peer averages or the fair ratio, the multiple could move up from current levels rather than down.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Aisin</a></p> <p><strong>Result: Price-to-earnings of 12.2x (UNDERVALUED)</strong></p> <p>However, investors still need to watch for any slowdown in annual revenue and net income growth and for how the leadership shift affects execution on Aisin's broad product portfolio.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Aisin narrative.</a></p> <h2>Another view on Aisin's value using our DCF model</h2> <p>The P/E story suggests some room for upside, but our DCF model presents a stronger valuation case. On this measure, Aisin at ¬•2,779.5 is trading at a 45.4% discount to an estimated future cash flow value of ¬•5,091.84. This indicates a wider potential value gap.</p> <p>Such a gap can reflect genuine mispricing, or it can suggest that the market is more cautious about long term cash flows than the model assumes. Which side do you think has it right?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/automobiles/tse-7259/aisin-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"7259 Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/cd6c662b-4e1c-44a0-9aaa-494fb21fb423/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>7259 Discounted Cash Flow as at Mar 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Aisin for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>The mix of potential upside and clear risks is hard to ignore, so take a moment to review the details yourself and move quickly if you want to shape your own view. Start with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a>.</p> <h2>Ready for more investment ideas?</h2> <p>If you stop with just one stock on your radar, you could miss other opportunities that better fit your goals, risk comfort and income needs.</p> <ul> <li>Target potential mispricings by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a> that pair solid fundamentals with price tags that may not fully reflect their underlying businesses yet.</li> <li>Build a steadier income stream by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 dividend fortresses</a> that focus on higher yields and balance sheet support for those payouts.</li> <li>Stay on the front foot with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/jp\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 58 high quality undiscovered gems</a> that highlight quality names many investors may not be watching closely yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:46:58",
            "link": "https://simplywall.st/stocks/jp/automobiles/tse-7259/aisin-shares/news/a-look-at-aisin-tse7259-valuation-after-leadership-transitio",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Will A++ Upgrade and New Debt Deal Change RLI's (RLI) Risk‚ÄëReward Narrative for Investors?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In late February 2026, RLI Corp. completed a US$300 million fixed-rate senior unsecured bond offering of 5.375% Notes due June 1, 2036, following a new debt shelf registration and alongside a board decision to maintain its quarterly dividend at US$0.16 per share, extending a 50-year dividend increase streak. </li> <li>A recent AM Best upgrade of RLI Group‚Äôs financial strength rating to A++, coupled with an equity-backed partnership with AI-focused insurer Kettle to launch a new multi-peril commercial property product including wildfire coverage, highlights both balance sheet strength and a push into more specialized, technology-enabled insurance solutions. </li> <li>We‚Äôll now examine how the AM Best upgrade to A++ reshapes RLI‚Äôs existing investment narrative and risk-reward trade-offs for investors.</li> </ul><p>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>RLI Investment Narrative Recap</h2><p>To own RLI, you have to be comfortable with a specialty insurer that leans heavily on underwriting discipline, a strong balance sheet and steady capital return. Right now, the main near term catalyst is whether underwriting profitability can stay resilient as commercial property conditions soften, while the biggest risk remains higher catastrophe losses and volatility in property results. The AM Best upgrade and new bond issue support financial flexibility, but do not fundamentally change that risk profile in the short term.</p> <p>Among the recent announcements, the AM Best upgrade to A++ stands out as most relevant. A higher financial strength rating can support RLI‚Äôs ability to write specialty business and access reinsurance on better terms, which matters if catastrophe claims stay elevated. Coupled with the Kettle partnership on multi peril property including wildfire, it ties directly into the key catalyst of maintaining attractive margins while taking on complex climate exposed risks.</p> <p>Yet, while the rating upgrade looks reassuring, investors should also be aware of how rising catastrophe exposure could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/insurance/nyse-rli/rli/9jnythxt-rli-future-performance-will-be-supported-by-strong-operational-execution\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on RLI (it's free!)</a></p><p>RLI's narrative projects $1.9 billion revenue and $297.9 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/insurance/nyse-rli/rli/9jnythxt-rli-future-performance-will-be-supported-by-strong-operational-execution\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how RLI's forecasts yield a $59.75 fair value</a>, a 4% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/insurance/nyse-rli/rli\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"RLI 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7a39d565-7db6-41e4-bfa5-9e5fa29b07bf/chart/quote-price\" width=\"746\"/></a><figcaption>RLI 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts saw RLI reaching about US$1.9 billion of revenue and US$345.9 million of earnings, but the new A++ rating and wildfire exposed products could either support that upbeat view or highlight how much their optimism depends on underwriting and catastrophe risk not breaking the thesis you just read about.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/insurance/nyse-rli/rli\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on RLI</a> - why the stock might be worth just $59.75!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your RLI research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/insurance/nyse-rli/rli\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/insurance/nyse-rli/rli\" rel=\"noopener noreferrer\" target=\"_blank\">Our free RLI research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate RLI's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 stocks that are working to make quantum computing a reality</a>.</li><li>Outshine the giants: these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 early-stage AI stocks could fund your retirement</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 19:46:58",
            "link": "https://simplywall.st/stocks/us/insurance/nyse-rli/rli/news/will-a-upgrade-and-new-debt-deal-change-rlis-rli-riskreward",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Greif (GEF) Valuation As Mixed Near‚ÄëTerm Returns Contrast With Longer‚ÄëTerm Gains",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Greif stock moves and recent performance snapshot</h2> <p>Greif (GEF) has attracted fresh attention after a period of mixed short term returns, including a 0.1% one day slip and a 2.6% decline over the past week, alongside positive longer term performance.</p> <p>With the shares last closing at US$72.67 and total return figures of 3% over the past month and 9.4% over the past 3 months, investors are reassessing how this industrial packaging company fits into their portfolios.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-gef/greif\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Greif.</a></p> <p>Greif‚Äôs recent share price pullback over the past week sits against a stronger backdrop, with positive share price returns over the past quarter and year and a solid 1 year total shareholder return of 31.5% suggesting earlier optimism is being reassessed rather than reversed.</p> <p>If this shift in momentum has you thinking about where else capital could work hard, it may be worth scanning our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a> as a starting point for fresh ideas.</p> <p>With Greif trading at US$72.67, sitting below the US$80.20 analyst price target and suggesting a roughly 53% intrinsic discount, you have to ask: is this a genuine value gap or is the market already factoring in future growth?</p> <h2>Most Popular Narrative: 8.7% Undervalued</h2> <p>Greif‚Äôs most followed narrative places fair value at $79.60, above the last close at $72.67, which sets up a clear valuation gap for investors to weigh.</p> <blockquote> <p><em>The company's investment and expansion in polymer-based packaging (with strong end-market demand in agrochemicals, pharma, food &amp; beverage, and flavor &amp; fragrance) directly positions Greif to benefit from the ongoing expansion of global manufacturing, logistics, and e-commerce, supporting sustainable top-line revenue growth.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/000ok5yw-gef-balance-sheet-flexibility-and-asset-sales-will-drive-future-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious what turns that growth story into a higher fair value? The narrative leans on changing margins, a reset revenue path, and a richer future earnings multiple. Want the full picture yet?</p> <p><strong>Result: Fair Value of $79.60 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/000ok5yw-gef-balance-sheet-flexibility-and-asset-sales-will-drive-future-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also need to factor in softer volumes in key packaging segments and execution risk if targeted polymer end markets or containerboard pricing do not play out as expected.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-gef/greif\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Greif narrative.</a></p> <h2>Another Angle On Valuation: Earnings Multiple Sends A Different Signal</h2> <p>While the popular narrative points to an 8.7% undervaluation, the current P/E of 22.2x sits above the fair ratio of 17.3x, the North American packaging average of 21.2x, and the peer average of 20.1x. That richer multiple can mean less room for error if growth expectations slip. Which signal do you trust more?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-gef/greif/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-gef/greif/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:GEF P/E Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/6adfc0be-7f92-4c6e-83e1-0f0cfa79593b/chart/pe-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NYSE:GEF P/E Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>Seeing mixed signals on Greif and wondering what it really adds up to for you? Act while the data is fresh and shape your own view by weighing its <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-gef/greif\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Greif has sparked your interest, do not stop here. Your next strong idea could be one smart screener away on Simply Wall St.</p> <ul> <li>Target value opportunities by scanning companies our screener flags as <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> with solid fundamentals already laid out for you.</li> <li>Prioritise resilience first and shortlist businesses identified as <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> so you can focus your research where risk scores already look more controlled.</li> <li>Hunt for lesser known prospects through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before the crowd starts paying attention.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:46:58",
            "link": "https://simplywall.st/stocks/us/materials/nyse-gef/greif/news/assessing-greif-gef-valuation-as-mixed-nearterm-returns-cont",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Sealed Air (SEE) Valuation As Shares Trade Near Recent Levels",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Why Sealed Air is on investors‚Äô radar today</h2> <p>Sealed Air (SEE) is back in focus after recent trading left the shares around $41.88, prompting investors to reassess how its packaging business and current valuation line up with their expectations.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-see/sealed-air\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Sealed Air.</a></p> <p>While the 1-day and 7-day share price returns are slightly negative, Sealed Air‚Äôs 1-year total shareholder return of 25.46% contrasts with weaker 3-year and modest 5-year total shareholder returns, which suggests that momentum has recently improved after a softer multi year period.</p> <p>If Sealed Air has you rethinking where packaging and automation fit in your portfolio, it could be a good time to scan <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a> as potential long term compounders beyond this sector.</p> <p>With Sealed Air trading around $41.88, showing recent 1 year gains but weaker 3 year and modest 5 year total returns, the key question is whether today‚Äôs valuation still leaves room for upside or if the market is already factoring in future growth.</p> <h2>Most Popular Narrative: 7% Undervalued</h2> <p>With Sealed Air last closing at $41.88 against a narrative fair value of about $45.02, the widely followed view sees modest upside still on the table.</p> <blockquote> <p><em>Ongoing investments in network optimization (new manufacturing facilities, supply chain streamlining, leveraging external R&amp;D/production partners) are expected to improve efficiency and customer service while reducing capital intensity, supporting both future margin expansion and free cash flow generation.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/6jorsoga-see-upcoming-cfo-appointment-and-product-advances-will-drive-shareholder-value\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of margin profile and earnings power that sort of efficiency story needs to support this value gap? The narrative quietly bakes in measured revenue growth, firmer profitability, and a leaner capital base that all have to work together to justify that fair value line.</p> <p><strong>Result: Fair Value of $45.02 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/6jorsoga-see-upcoming-cfo-appointment-and-product-advances-will-drive-shareholder-value\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also have to weigh risks such as a prolonged slump in high margin beef volumes or ongoing pricing pressure in Protective packaging that could squeeze earnings.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-see/sealed-air\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Sealed Air narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of potential upside and real risks feels finely balanced, do not wait around. Review the numbers yourself and see how <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-see/sealed-air\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 1 important warning sign</a> stack up for your view on Sealed Air.</p> <h2>Looking for more investment ideas?</h2> <p>Do not stop with one stock. The Simply Wall St screener can quickly surface other ideas that might fit your goals and help you act with confidence.</p> <ul> <li>Target steadier returns by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a>, which score well on resilience when markets feel uncertain.</li> <li>Hunt for value by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a>, which pair solid fundamentals with relatively low market attention.</li> <li>Strengthen your income stream by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a>, which focus on higher yields with an emphasis on resilience.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:41:37",
            "link": "https://simplywall.st/stocks/us/materials/nyse-see/sealed-air/news/assessing-sealed-air-see-valuation-as-shares-trade-near-rece",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing‚Äôs syndrome therapy Recorlev until its patents expire in March 2040.</li> <li>This legal move highlights how central Recorlev‚Äôs intellectual property protection is to Xeris‚Äôs long-term product exclusivity and potential revenue longevity in its endocrine franchise.</li> <li>We‚Äôll now examine how this patent lawsuit, aimed at preserving Recorlev‚Äôs market exclusivity, could influence Xeris Biopharma‚Äôs broader investment narrative.</li> </ul><p>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Xeris Biopharma Holdings Investment Narrative Recap</h2><p>To own Xeris Biopharma, you have to believe its focused endocrine portfolio, anchored by Recorlev, can support a path to sustainable profitability while the company invests in growth. The Recorlev patent lawsuit is important for protecting potential long term cash flows, but in the near term the key catalyst is still execution around upcoming earnings and commercial performance, while the biggest risk remains Xeris‚Äôs reliance on a small set of branded products.</p> <p>Against this backdrop, the upcoming March 2, 2026 earnings report, with consensus expecting US$0.04 EPS and full year 2025 revenue around US$292,000,000, looks especially relevant. Those results will give investors a fresh read on how Recorlev, Gvoke, and Keveyis are performing just as Xeris moves to defend Recorlev‚Äôs patents, and may influence how investors weigh the benefit of extended exclusivity against ongoing R&amp;D and SG&amp;A spending.</p> <p>Yet while the lawsuit aims to secure Recorlev‚Äôs future, investors should also factor in the risk that...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/9pjzm8dt-xers-higher-2025-revenue-guidance-will-drive-measured-financial-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Xeris Biopharma Holdings (it's free!)</a></p><p>Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/9pjzm8dt-xers-higher-2025-revenue-guidance-will-drive-measured-financial-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value</a>, a 82% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"XERS 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/34985fb8-c88a-498a-8524-1011a674e966/chart/quote-price\" width=\"746\"/></a><figcaption>XERS 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest estimating analysts were already more cautious, even while assuming revenue could reach about US$414,200,000 and earnings about US$21,400,000 by 2028, so this fresh legal uncertainty around Recorlev‚Äôs patents could push their already more pessimistic view further, and it is worth asking yourself which version of Xeris‚Äôs future you find more convincing.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 4 other fair value estimates on Xeris Biopharma Holdings</a> - why the stock might be worth 23% less than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Xeris Biopharma Holdings research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>Outshine the giants: these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 early-stage AI stocks could fund your retirement</a>.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 19:41:37",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/xeris-biopharma-holdings-xers-is-down-74-after-suing-to-bloc",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Tokyu Fudosan Holdings (TSE:3289) Valuation After New ¬•10b Green Bond Issuance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Tokyu Fudosan Holdings (TSE:3289) has drawn fresh attention after completing a ¬•10 billion unsecured green bond offering, featuring a 1.904% fixed coupon due March 12, 2031, following several climate focused issuances.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Tokyu Fudosan Holdings.</a></p> <p>The green bond issuance comes as Tokyu Fudosan Holdings‚Äô share price sits at ¬•1,570.5, with a 30 day share price return of 11.42% and a 1 year total shareholder return of 67.00%, pointing to momentum that has built over time rather than overnight.</p> <p>If this sustainable finance move has you thinking about where else long term themes could play out, it may be worth checking our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as another way to look for potential ideas.</p> <p>With annual revenue of ¬•1,219,274 million and net income of ¬•92,302 million, but a value score of 3 and the share price sitting slightly above analyst targets, investors may wonder whether there is still an attractive entry point or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Preferred P/E of 12.1x: Is it justified?</h2> <p>Tokyu Fudosan Holdings trades on a P/E of 12.1x, while our data suggests a fair P/E closer to 16.2x. This points to a discount at the current ¬•1,570.5 share price.</p> <p>The P/E ratio compares the current share price with earnings per share, so it effectively tells you how much investors are paying for each unit of earnings. For a real estate group that is already profitable and generating net income of ¬•92,302 million, P/E is a straightforward way to gauge how the market is pricing those earnings today.</p> <p>Here, the company screens as good value against several yardsticks. The current 12.1x P/E is below the estimated fair P/E of 16.2x. It also sits below the peer average of 14.3x, the Japan real estate industry average of 12.8x, and the broader Japan market at 15.6x. That combination suggests the market is pricing Tokyu Fudosan Holdings at a lower earnings multiple than these reference points, while our fair ratio work points to a level the market could move towards if perceptions of its earnings strength and growth potential align with those benchmarks.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Tokyu Fudosan Holdings</a></p> <p><strong>Result: Price-to-earnings of 12.1x (UNDERVALUED)</strong></p> <p>However, you are still relying on analyst estimates for that fair P/E, and on earnings that tie closely to real estate and energy markets, which can be cyclical.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Tokyu Fudosan Holdings narrative.</a></p> <h2>Another View: DCF Paints A Different Picture</h2> <p>While the 12.1x P/E suggests Tokyu Fudosan Holdings looks inexpensive, our DCF model points a very different way. It indicates an estimated future cash flow value of ¬•654.05 compared with the current ¬•1,570.5 share price. On that basis, the shares screen as overvalued rather than cheap. Which signal do you give more weight to?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"3289 Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/71e593e0-35d8-457b-ac3b-511c0da81d9f/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>3289 Discounted Cash Flow as at Mar 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Tokyu Fudosan Holdings for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Confused by the mixed signals so far? Take a moment to review the numbers yourself and weigh up <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a> before you decide what it all means.</p> <h2>Ready to hunt for your next idea?</h2> <p>If you stop with just one company, you could miss opportunities that fit your style far better, so put the Simply Wall St screener to work for you.</p> <ul> <li>Target potential value by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a> that combine quality fundamentals with prices that may not fully reflect their strengths.</li> <li>Prioritise resilience by checking our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/jp\" rel=\"noopener noreferrer\" target=\"_blank\">56 resilient stocks with low risk scores</a> that score well on risk factors and aim to keep surprises to a minimum.</li> <li>Get ahead of the crowd by reviewing a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/jp\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 58 high quality undiscovered gems</a> that the market may not be paying close attention to yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Tokyu Fudosan Holdings might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 19:41:37",
            "link": "https://simplywall.st/stocks/jp/real-estate-management-and-development/tse-3289/tokyu-fudosan-holdings-shares/news/a-look-at-tokyu-fudosan-holdings-tse3289-valuation-after-new",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Allient (ALNT) Valuation As Operational Headwinds And Capital Choices Pressure Growth",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Allient‚Äôs recent challenges come into focus</h2> <p>Recent commentary on Allient (ALNT) has focused on two years of annual sales and earnings declines, alongside new share issuances and weaker returns on capital, raising fresh questions about how efficiently the business is being run.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-alnt/allient\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Allient.</a></p> <p>Allient‚Äôs recent share price has eased back, with a 1-day share price return of a 1.9% decline and a 7-day share price return of a 3.7% decline. However, the 90-day share price return of 23.9% and 1-year total shareholder return of 165.6% point to earlier, much stronger positive momentum that now appears to be cooling.</p> <p>If Allient‚Äôs recent swings have you reassessing your ideas, this could be a good moment to broaden your search and check out our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With Allient trading around US$65.84, above the US$58.50 analyst target and with an intrinsic value flag that suggests a premium, you have to ask: is there still a buying opportunity here, or is future growth already priced in?</p> <h2>Most Popular Narrative: 24.1% Overvalued</h2> <p>With Allient at $65.84 against a most-followed fair value estimate of about $53.07, the current price sits well above that narrative benchmark.</p> <blockquote> <p><em>The analysts have a consensus price target of $39.333 for Allient based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $51.0, and the most bearish reporting a price target of just $32.0.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/2vi8rap3-alnt-sequential-sales-decline-will-drive-shares-below-current-levels\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious how a business with moderate revenue assumptions and a step up in margins still lands on a fair value below today‚Äôs price? The narrative leans on a specific earnings path, a tighter share count view, and a future earnings multiple that is lower than where the market is right now. The tension between those inputs and the current share price is where the full story gets interesting.</p> <p><strong>Result: Fair Value of $53.07 (OVERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/2vi8rap3-alnt-sequential-sales-decline-will-drive-shares-below-current-levels\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, if Allient sustains margin gains from its Simplify to Accelerate NOW program or executes earnings accretive M&amp;A, that overvaluation narrative could be challenged.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-alnt/allient\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Allient narrative.</a></p> <h2>Next Steps</h2> <p>With the story feeling mixed, with both questions and potential upside in play, it makes sense to move quickly, review the data yourself, and see how our breakdown of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-alnt/allient\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> lines up with your own view.</p> <h2>Looking for more investment ideas?</h2> <p>If Allient feels fully priced, do not sit on the sidelines. Put your watchlist to work by checking fresh ideas our screeners surface every day.</p> <ul> <li>Target quality at a discount by reviewing our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that pair solid fundamentals with prices below their fair value estimates.</li> <li>Prioritise resilience with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> that focus on companies with steadier risk profiles and fewer financial red flags.</li> <li>Spot future standouts early through a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that highlights companies with strong fundamentals that many investors may be overlooking.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:41:37",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-alnt/allient/news/assessing-allient-alnt-valuation-as-operational-headwinds-an",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Glaukos (GKOS) Valuation Check As iDose Sales Momentum Meets Impairment Charge And Upbeat 2026 Outlook",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Glaukos.</a></p> <p>The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests momentum has been building rather than fading around Glaukos' product and sales story.</p> <p>If Glaukos' latest update has you thinking more broadly about medical and eye care opportunities, this is a good moment to scan our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> for potential next ideas.</p> <p>With Glaukos trading at US$120.40, sitting at a discount to one set of analyst targets and flagged as intrinsically discounted, the key question is whether that suggests an opportunity or if the market price already reflects future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 8.6% Undervalued</h2> <p>Glaukos is trading at $120.40 against a widely followed fair value of about $131.77, and that gap rests heavily on how iDose and the broader pipeline play out.</p> <blockquote> <p><em>Glaukos' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/rhplkfbe-gkos-momentum-from-recent-regulatory-wins-will-drive-outperformance-through-2026\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of revenue runway and margin profile are baked into that fair value, and how rich the implied future earnings multiple really is.</p> <p><strong>Result: Fair Value of $131.77 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/rhplkfbe-gkos-momentum-from-recent-regulatory-wins-will-drive-outperformance-through-2026\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, that fair value gap can close quickly if iDose adoption, repeat dosing or reimbursement trends fall short, or if new glaucoma competitors gain share faster than expected.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Glaukos narrative.</a></p> <h2>Another View On Valuation</h2> <p>That $131.77 fair value from the narrative contrasts sharply with how the market is pricing Glaukos on sales today. At a P/S of 13.8x versus an industry average of 2.9x and a fair ratio of 7.4x, the shares carry a rich revenue multiple that raises the bar for future execution.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/healthcare/nyse-gkos/glaukos/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:GKOS P/S Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/e612017b-7a6e-4ed6-9c5d-d6b5c57650dd/chart/ps-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NYSE:GKOS P/S Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If the mix of optimism and caution here feels familiar, this is the moment to look through the numbers yourself and move quickly to your own view, then see how that lines up with the <a class=\"company-report-links\" data-vars-link-type=\"cta_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards</a>.</p> <h2>Ready to hunt for your next idea?</h2> <p>If you stop at Glaukos, you could miss other opportunities that better match your style. Use this moment to widen your watchlist with purpose.</p> <ul> <li>Target dependable cash generators with strong payouts by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that may suit income focused portfolios.</li> <li>Spot potential bargains before they hit the spotlight by running through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> built around quality fundamentals.</li> <li>Prioritise resilience and sleep better at night by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> designed for investors who care about steadier risk profiles.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:36:38",
            "link": "https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/glaukos-gkos-valuation-check-as-idose-sales-momentum-meets-i",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Does SiteMinder‚Äôs Narrower Half-Year Loss Reshape The Profitability Story For SiteMinder (ASX:SDR)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>SiteMinder Limited reported half-year results for the period ended 31 December 2025, with sales of A$131.1 million and a reduced net loss of A$4.78 million compared with the prior year.</li> <li>The smaller basic and diluted loss per share of A$0.02 highlights how the company‚Äôs profitability metrics have improved even as it continues to operate at a loss.</li> <li>Next, we‚Äôll examine how SiteMinder‚Äôs higher sales and narrower loss shape its investment narrative in light of recent share price moves.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is SiteMinder's Investment Narrative?</h2><p>To own SiteMinder today, you need to believe its growing A$131.1 million half-year sales base can eventually support sustainable profits, despite the business still being loss-making. The latest result, with a reduced A$4.78 million net loss and a smaller A$0.02 loss per share, reinforces the core short term catalyst: further operating leverage as revenue scales. It also slightly softens one of the key risks highlighted earlier, that ongoing cash burn could require fresh capital if progress stalled. That said, the sharp share price pullback over the past quarter suggests the market remains cautious about execution, competitive pressures and the timing of any move into profitability. In that context, this half-year update helps, but does not remove, the central risk that profitability could take longer or prove harder than expected.</p> However, one risk around future funding needs is something investors should pay close attention to.\n\nDespite retreating, SiteMinder's shares might still be trading 38% above their fair value. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/au/software/asx-sdr/siteminder-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Discover the potential downside here</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/software/asx-sdr/siteminder-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:SDR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b2979078-1620-4ca0-a9bd-9c9d16b95979/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:SDR 1-Year Stock Price Chart</figcaption></figure> Ten fair value views from the Simply Wall St Community span A$4.40 to A$10.75, underlining how far opinions can stretch. Set against recent progress in narrowing losses, this spread invites you to weigh improving metrics against execution and funding risks that could still shape SiteMinder‚Äôs longer term performance.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-sdr/siteminder-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 10 other fair value estimates on SiteMinder</a> - why the stock might be worth over 2x more than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your SiteMinder research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/software/asx-sdr/siteminder-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/software/asx-sdr/siteminder-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free SiteMinder research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SiteMinder's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/au\" rel=\"noopener noreferrer\" target=\"_blank\">7 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/au\" rel=\"noopener noreferrer\" target=\"_blank\">10 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:36:38",
            "link": "https://simplywall.st/stocks/au/software/asx-sdr/siteminder-shares/news/does-siteminders-narrower-half-year-loss-reshape-the-profita",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Piper Sandler (PIPR) Quietly Recasting Its Healthcare Brand Around High-Margin Advisory Niches?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Piper Sandler Companies recently expanded its healthcare investment banking franchise, appointing Jason Arnold as a managing director focused on life science tools and diagnostics and naming Aamer Naseer global head of life sciences outsourcing and B2B med tech.</li> <li>These hires deepen Piper Sandler‚Äôs sector expertise at a time when life sciences outsourcing and diagnostics are increasingly central to healthcare deal and capital-raising activity.</li> <li>We‚Äôll now examine how this refreshed life sciences leadership bench could shape Piper Sandler‚Äôs investment narrative, especially around healthcare-focused capital markets growth.</li> </ul><p>Find <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Piper Sandler Companies Investment Narrative Recap</h2><p>To own Piper Sandler today, you need to believe its sector focused investment banking model can keep translating specialized advice in areas like healthcare into resilient fee pools, even as market conditions and deal volumes shift. The refreshed life sciences leadership looks additive but does not fundamentally change the near term picture, where the key catalyst is sustained healthcare capital markets activity and the biggest risk remains a pullback in broader equity and financing markets that could slow underwriting and advisory pipelines.</p> <p>Among recent developments, the strong Q4 2025 results, with revenue rising to US$666.99 million and earnings beating expectations, stand out as most relevant. They underline how active healthcare, public finance and sponsor related activity can support earnings when pipelines are healthy, but they also frame the risk that a reversal in equity markets or weaker depository valuations could quickly weigh on transaction volumes and margins if sentiment turns.</p> <p>Yet investors should be aware that if equity markets lose momentum or volatility spikes, the firm‚Äôs dependence on underwriting and M&amp;A activity could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nyse-pipr/piper-sandler-companies/96sv0266-update-for-piper-sandler-companies\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Piper Sandler Companies (it's free!)</a></p><p>Piper Sandler Companies' narrative projects $2.5 billion revenue and $448.7 million earnings by 2029. This requires 13.8% yearly revenue growth and a $212.3 million earnings increase from $236.4 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nyse-pipr/piper-sandler-companies/96sv0266-update-for-piper-sandler-companies\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Piper Sandler Companies' forecasts yield a $410.67 fair value</a>, a 39% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/diversified-financials/nyse-pipr/piper-sandler-companies\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PIPR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b14345f3-bfb5-4701-9a35-ac04f818a779/chart/quote-price\" width=\"746\"/></a><figcaption>PIPR 1-Year Stock Price Chart</figcaption></figure> <p>Three members of the Simply Wall St Community currently peg Piper Sandler‚Äôs fair value between US$64.53 and US$422.67, underscoring just how far opinions can differ. Against that backdrop, the reliance on healthy equity markets and deal activity to support underwriting and advisory revenue growth is a key consideration you should weigh when comparing these views.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nyse-pipr/piper-sandler-companies\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Piper Sandler Companies</a> - why the stock might be worth as much as 43% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Piper Sandler Companies research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nyse-pipr/piper-sandler-companies\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nyse-pipr/piper-sandler-companies\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Piper Sandler Companies research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Piper Sandler Companies' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The latest GPUs need a type of rare earth metal called Neodymium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:36:38",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-pipr/piper-sandler-companies/news/is-piper-sandler-pipr-quietly-recasting-its-healthcare-brand",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Whether United Community Banks (UCB) Still Looks Undervalued After Recent Share Price Weakness",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Without a specific news announcement driving attention today, United Community Banks (UCB) still offers investors concrete data points to consider, including recent share performance, profitability metrics, and value-focused scores.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/banks/nyse-ucb/united-community-banks\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for United Community Banks.</a></p> <p>At a share price of $32.17, United Community Banks has seen a 6.56% 1 month share price decline, while its 90 day share price return of 3.91% and 1 year total shareholder return of 3.10% point to relatively modest, but positive, longer term momentum.</p> <p>If this kind of mixed banking performance has your attention, it could be a good moment to broaden your search with our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With United Community Banks trading at $32.17, a 16.05% discount to the average analyst price target and a reported 45.16% intrinsic discount, it is worth considering whether there is genuine value here or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 13.8% Undervalued</h2> <p>With United Community Banks last closing at $32.17 against a narrative fair value of about $37.33, the gap comes down to how future earnings, margins, and the chosen discount rate interact over time.</p> <blockquote> <p><em>Ongoing diversification of income streams, including fee income from wealth management, mortgage banking, and loan sales, reduces reliance on net interest income and stabilizes earnings, particularly benefitting long-term return on equity and mitigating downside risk from interest rate volatility.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/lcl04j1m-southeastern-migration-and-digital-efficiency-will-drive-future-expansion-va5w\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what underpins that fair value gap? The narrative leans heavily on compounding revenue, higher profit margins, and a future earnings multiple that assumes those trends continue. Curious which specific growth and margin assumptions have been incorporated into that 6.98% discount rate and the 2028 earnings outlook? The full narrative breaks down exactly how those moving parts line up.</p> <p><strong>Result: Fair Value of $37.33 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/lcl04j1m-southeastern-migration-and-digital-efficiency-will-drive-future-expansion-va5w\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, that upside story can quickly change if competition pressures deposit growth or if commercial real estate and specialized lending exposures lead to weaker asset quality.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/banks/nyse-ucb/united-community-banks\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this United Community Banks narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of potential upside and real risks leaves you on the fence, now is a good time to look through the full picture yourself and weigh <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/banks/nyse-ucb/united-community-banks\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If you stop here, you miss a broader set of opportunities. Use the Simply Wall St Screener to pressure test your thinking across different types of stocks.</p> <ul> <li>Target dependable income by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that focus on higher-yielding payers with a focus on resilience.</li> <li>Spot potential value opportunities early with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that score well on quality and pricing metrics.</li> <li>Prioritize capital protection first by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> that aim to keep risk scores on the lower side.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 19:36:38",
            "link": "https://simplywall.st/stocks/us/banks/nyse-ucb/united-community-banks/news/assessing-whether-united-community-banks-ucb-still-looks-und",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Willdan Group (WLDN) Valuation After Record Results And New US$49 Million Energy Contract",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Willdan Group (WLDN) is back in focus after reporting higher fourth quarter and full year revenue and net income, alongside a new US$49 million energy services contract with Mt. San Antonio College in California.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Willdan Group.</a></p> <p>Despite the strong contract wins and record financial results, Willdan Group‚Äôs share price has seen a sharp pullback recently, with a 1 day share price return of negative 25.47% and a 30 day share price return of negative 29.37%. At the same time, the 1 year total shareholder return sits at 172.60%, which points to fading short term momentum after a very strong multi year run.</p> <p>If this volatility has you thinking about where else growth and infrastructure themes might show up in your portfolio, you can scan our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> for other grid focused names that may be worth a closer look.</p> <p>With the share price pulling back after record results, yet still sitting on a very large 1 year total return and trading below some analyst targets, you have to ask: is Willdan now undervalued, or is the market already pricing in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 38.5% Undervalued</h2> <p>With Willdan Group last closing at $89.14 against a narrative fair value of $145, the current share price sits well below that central estimate, setting up a clear gap between market pricing and this widely followed view.</p> <blockquote> <p><em>Long term and increasing utility and municipal contracts, typically 3 to 5 years in duration and funded through stable sources, are contributing to recurring revenue and improved earnings visibility, reducing earnings volatility and supporting higher net margins.</em></p> <p><em>Ongoing investments and planning for grid modernization, combined with the company's strong reputation with utility commissions and government agencies, position Willdan to benefit disproportionately from federal/state decarbonization mandates and infrastructure modernization initiatives, supporting sustained revenue and EBITDA growth over the long term.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/7vftqh7c-electrification-and-ai-data-centers-will-empower-grid-modernization-twpf\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious what has to happen for that higher fair value to stack up? The narrative leans on rising earnings power, thicker margins, and a future profit multiple that assumes Willdan keeps winning and scaling complex energy projects. The exact mix of revenue growth, profitability and required return might surprise you.</p> <p><strong>Result: Fair Value of $145 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/7vftqh7c-electrification-and-ai-data-centers-will-empower-grid-modernization-twpf\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you still need to weigh risks around policy shifts for utility funded energy projects, as well as potential margin pressure if higher costs or tax changes bite harder than expected.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Willdan Group narrative.</a></p> <h2>Another Angle: Earnings Multiple Paints A Tougher Picture</h2> <p>While the SWS DCF model and analyst narrative suggest Willdan Group looks undervalued, the P/E ratio tells a more cautious story. At around 25x earnings versus 16.2x for peers and 20.2x for the broader US Professional Services industry, the stock is not cheap on this yardstick. How comfortable are you paying that premium?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nasdaq-wldn/willdan-group/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:WLDN P/E Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3e16d40e-9758-4725-b423-4aada866e78c/chart/pe-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NasdaqGM:WLDN P/E Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If this mix of optimism and concern feels familiar, now is a good time to look through the numbers yourself and decide what really matters for you as an investor, and our breakdown of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> can help you weigh those trade offs clearly.</p> <h2>Looking for more investment ideas?</h2> <p>If Willdan has you thinking about what else could fit your watchlist, do not stop here. Broaden your view and put a few more ideas on the table.</p> <ul> <li>Target dependable cash generators by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that focus on income potential backed by higher yields.</li> <li>Hunt for quality at a discount using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that highlight companies with strong fundamentals that many investors may still be overlooking.</li> <li>Prioritise resilience with the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> that surfaces businesses with lower risk scores if you want a calmer ride through market swings.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Willdan Group might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/commercial-services/nasdaq-wldn/willdan-group/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 19:30:57",
            "link": "https://simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group/news/a-look-at-willdan-group-wldn-valuation-after-record-results",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Hokkaido Electric Power Company‚Äôs Valuation As Ishikariwan Shinko Expansion Plans Advance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Hokkaido Electric Power Company (TSE:9509) plans higher output and an earlier build schedule at its Ishikariwan Shinko LNG plant, moves that put its generation mix and supply reliability in sharper focus for shareholders.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Hokkaido Electric Power Company.</a></p> <p>The Ishikariwan Shinko update comes as momentum has been firming, with a 19.06% 1 month share price return, 11.86% year to date, and a 72.38% 1 year total shareholder return suggesting investors are reassessing both growth prospects and risk.</p> <p>If you are looking beyond utilities for what else is moving, our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> is a useful way to spot other electricity and grid related names catching attention.</p> <p>With the shares up sharply over 1 year and trading at a small discount to the ¬•1,340 analyst target, the key question is whether Hokkaido Electric still offers value or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Preferred P/E of 4.4x: Is it justified?</h2> <p>On a P/E of 4.4x and a last close of ¬•1,230.5, Hokkaido Electric trades slightly above its peer average but well below both the broader JP market and its own estimated fair ratio.</p> <p>The P/E multiple compares the current share price to earnings per share. For a utility like Hokkaido Electric it reflects what investors are willing to pay for each unit of earnings given its regulated returns, capital intensity and cash flow profile.</p> <p>Here, the stock is described as expensive versus its immediate peer average P/E of 4.2x. It is also framed as good value against the Asian Electric Utilities average of 17.6x and a fair P/E estimate of 9.5x, suggesting the market is pricing its earnings materially lower than the level that model implies it could move towards.</p> <p>Relative to the broader JP market P/E of 15.6x, the 4.4x P/E is also much lower, which again underlines how compressed the multiple looks compared with both domestic equities and the sector wide context.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Hokkaido Electric Power Company</a></p> <p><strong>Result: Price-to-Earnings of 4.4x (UNDERVALUED)</strong></p> <p>However, you still need to weigh regulatory changes or project delays at Ishikariwan Shinko that could affect earnings, cash flows, and how reliable that P/E looks.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Hokkaido Electric Power Company narrative.</a></p> <h2>Another view: DCF points the other way</h2> <p>While the 4.4x P/E suggests room to move closer to the 9.5x fair ratio, our DCF model is more conservative. On that approach, Hokkaido Electric at ¬•1,230.5 is trading above an estimated future cash flow value of ¬•870.28, which implies limited upside and some valuation risk. Which signal do you put more weight on: earnings today or cash flows projected ahead?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"9509 Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/c387b43e-a10f-4156-b065-ce343cad1687/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>9509 Discounted Cash Flow as at Mar 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Hokkaido Electric Power Company for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Feeling torn between the low P/E signal and the more cautious DCF view? Consider reviewing the full picture yourself, including <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this update on Hokkaido Electric has sharpened your thinking, do not stop here. Broaden your watchlist with a few targeted idea lists before you move on.</p> <ul> <li>Spot potential value opportunities by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a> that pair compressed valuations with solid business profiles.</li> <li>Strengthen your income watchlist by reviewing a hand picked set of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 dividend fortresses</a> that keep yield and resilience front of mind.</li> <li>Round out your research with a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/jp\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (35 results)</a> so you are not missing companies built on sturdier financial footing.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Hokkaido Electric Power Company might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 19:30:57",
            "link": "https://simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/news/assessing-hokkaido-electric-power-companys-valuation-as-ishi",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "What Growthpoint Properties Australia (ASX:GOZ)'s Return To Profitability And Steady 2026 Payout Means For Shareholders",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Growthpoint Properties Australia reported half-year 2025 results showing revenue of A$169.1¬†million and net income of A$65¬†million, alongside maintaining its fiscal 2026 distribution guidance at 18.4¬†cents per share.</li> <li>This shift from a very large prior half-year loss to profitability, while keeping distribution guidance unchanged, may influence how investors assess the reliability of the income stream.</li> <li>Now we‚Äôll examine how the return to profitability and maintained 2026 distribution guidance might reshape Growthpoint Properties Australia‚Äôs investment narrative.</li> </ul><p>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 stocks that are working to make quantum computing a reality</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Growthpoint Properties Australia Investment Narrative Recap</h2><p>To own Growthpoint Properties Australia, you need to be comfortable relying on a steady income-focused REIT that is working through a period of mixed financial metrics. The return to profitability in the half year and reaffirmed fiscal 2026 distribution guidance support the near term income story, but the key risk remains whether earnings and free cash flow are sufficient to comfortably cover those payouts and interest costs.</p> <p>The most relevant update here is the February 2026 half year result, with A$169.1 million of revenue and A$65 million of net income after a prior loss. When viewed alongside maintained 18.4 cents per share distribution guidance, this result helps frame how sustainable the current yield might be, especially given earlier periods of losses and the ongoing pressure on interest cover and payout coverage.</p> <p>Yet behind the return to profit, one issue investors should be aware of is the current dividend not being well covered by free cash flows, which could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/real-estate/asx-goz/growthpoint-properties-australia-shares/pf28jkku-update-for-growthpoint-properties-australia\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Growthpoint Properties Australia (it's free!)</a></p><p>Growthpoint Properties Australia's narrative projects A$349.0 million revenue and A$192.0 million earnings by 2028. This requires 2.5% yearly revenue growth and an earnings increase of A$316.6 million from A$-124.6 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/real-estate/asx-goz/growthpoint-properties-australia-shares/pf28jkku-update-for-growthpoint-properties-australia\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Growthpoint Properties Australia's forecasts yield a A$2.76 fair value</a>, a 23% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/real-estate/asx-goz/growthpoint-properties-australia-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:GOZ 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f55278f4-90c8-4616-99cc-c92b431ee7b7/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:GOZ 1-Year Stock Price Chart</figcaption></figure> <p>Three Simply Wall St Community fair value estimates cluster tightly between A$2.67 and A$2.76, underlining how closely some private investors are thinking about Growthpoint‚Äôs pricing. Set that against the maintained 18.4 cents per share distribution guidance and recent swing back to profit, and you can see why opinions on the resilience of this income stream and the company‚Äôs future performance may differ widely, encouraging you to weigh several viewpoints before deciding how it fits your portfolio.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/real-estate/asx-goz/growthpoint-properties-australia-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Growthpoint Properties Australia</a> - why the stock might be worth as much as 23% more than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Growthpoint Properties Australia research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/real-estate/asx-goz/growthpoint-properties-australia-shares\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/real-estate/asx-goz/growthpoint-properties-australia-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Growthpoint Properties Australia research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Growthpoint Properties Australia's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/au\" rel=\"noopener noreferrer\" target=\"_blank\">7 companies with promising cash flow potential yet trading below their fair value</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 19:30:57",
            "link": "https://simplywall.st/stocks/au/real-estate/asx-goz/growthpoint-properties-australia-shares/news/what-growthpoint-properties-australia-asxgozs-return-to-prof",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}